What does a new drug commercialisation pathway entail?
What are the time, financial and regulatory steps involved in developing a new drug and getting it to market?
By Campus+
Date and time
Thu, 1 Sep 2022 7:00 PM - 8:00 PM PDT
Location
Online
What are the time, financial and regulatory steps involved in developing a new drug and getting it to market?
Online
We are delighted to welcome Dr David Fuller, internationally experienced biopharmaceutical executive, to provide essential insights on what a new drug commercialisation pathway actually entails. This webinar will cover:
Meet your Presenter: Dr. David Fuller is currently Chief Medical Officer, Race Oncology and Chairman of EpiAxis Therapeutics, a privately owned epigenetic therapeutic and diagnostic company, and is a Non-Executive Director of the ASX- listed biotech company, AdAlta (ASX: 1AD). He has more than 30 years of R&D experience, spanning large, mid and small cap companies including pre-clinical and clinical development, medical and regulatory affairs, and commercialisation. Most recently Dr Fuller was the Senior Vice President of Clinical Development in the Oncology Business Unit at Syneos Health Clinical Solutions. Prior to this he was a Director at Linear Clinical Research, Chairman of Dimerix Bioscience, CMO/COO at Trident Clinical Research, CMO at Arana Therapeutics, and Vice-President Clinical at Genzyme Europe.
PD+ streams: MedTech and Life Sciences | Commercialisation of Research